Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SmithKline Beecham Twinrix

Executive Summary

Immunogencity rates following administration of the combination hepatitis A/hepatitis B vaccine Twinrix were statistically equivalent to protection from separately administered hep A (Havrix) and hep B (Engerix B) vaccines, Phase III data presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco indicate. The open-label study conducted at two centers evaluated 773 patients randomized to receive either three doses of Twinrix at 0, 1 and 6 months, or Havrix at 0 and 6 months and Engerix B at 0, 1 and 6 months. The combination vaccine "has the advantage of reducing the number of injections needed (3 vs. 5), increasing the convenience of administration and...compliance to vaccination schedules," SmithKline concluded. Twinrix, already approved in the U.K., is currently under review at FDA

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts